MaxCyte, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Maher Masoud
- Full Time Employees
- 114
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 9713 Key West Avenue Rockville MD United States of America 20850
- IPO Date
- Jul 30, 2021
- CIK
- 0001287098
- Website
- maxcyte.com
- Similar Companies
- Business
- MaxCyte, Inc. (NASDAQ: MXCT) is a leading cell engineering company that develops and provides non-viral cell engineering platform technologies for complex cellular therapeutic applications, including ex vivo and in vivo therapies across oncology, autoimmune diseases, and regenerative medicine. The company's core offerings include its proprietary Flow Electroporation® technology, delivered through the ExPERT™ family of instruments such as the ExPERT G4, ExPERT G16, ExPERT ATx, and ExPERT STx systems; associated disposable processing assemblies; and a comprehensive suite of services encompassing nucleic acid production, technical application support, and analytical services. MaxCyte operates primarily in the United States and Europe, serving pharmaceutical and biotechnology partners developing clinical-stage therapies via its Processing-as-a-Service® model and strategic partnerships. Founded in 1998 and headquartered in Rockville, Maryland, the company focuses on enabling scalable, reproducible cell engineering for next-generation therapies targeting large patient populations. In recent developments, MaxCyte expanded its pipeline through a high-value strategic partnership with Strategy Therapeutics for its CAR T-cell therapy program, achieved key milestones in ongoing collaborations including the TSC-100 and TSC-101 programs with Takeda, and reported positive Phase 1 clinical data for multiple partnered programs, reinforcing its position in non-viral gene editing technologies [ from previous searches, company website inferred].
MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript
MaxCyte Q1 Earnings Call Highlights
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
MaxCyte, Inc. (NASDAQ:MXCT) Receives $5.50 Average Price Target from Analysts
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MaxCyte Q4 Earnings Call Highlights
MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript
MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO
MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript
MaxCyte Announces Planned CFO Transition in 2026
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance